



## The latest addition to CSAN®: CSAN® Pronto®

HLS Therapeutics Inc. is committed to finding solutions to help optimize the full patient journey, including routine clozapine bloodwork. As a result, HLS Therapeutics Inc. is pleased to introduce **CSAN® Pronto®**, a **capillary point-of-care (POC) device intended to enhance the mandatory safety blood monitoring requirement** for patients that are prescribed CLOZARIL® (clozapine).

CSAN® Pronto® enables patients to have their bloodwork performed in-office, generating white blood cell counts and neutrophil percentage during their visit. By bridging the gap between essential bloodwork and the efficiencies you need, our goal is to alleviate the burden on both your patients and you so that more time can be spent on what matters most—caring for patients.

### How can fast, integrated, lab-quality results with CSAN® Pronto® help?

By accelerating treatment decisions and putting patients at the heart of decision-making, this latest addition to the CSAN® program is designed to power a new era of personalized care for patients with TRS by:

1. **Offering convenience of onsite testing with the point of care testing system**
2. **Enhancing continuity of care**
3. **Providing seamless integration into your patients' existing CSAN® profiles.**



To learn more, visit [www.CSANPronto.ca](http://www.CSANPronto.ca) or call CSAN® at 1-800-267-2726.

CLOZARIL® (clozapine) is indicated in the management of symptoms of treatment-resistant schizophrenia.<sup>1</sup>

Please consult the CLOZARIL® Product Monograph at [http://www.hls therapeutics.com/wp-content/uploads/monograph\\_pdf/HLS-Clozaril-PM-E.pdf](http://www.hls therapeutics.com/wp-content/uploads/monograph_pdf/HLS-Clozaril-PM-E.pdf) for important information on contraindications, warnings, precautions, adverse reactions, drug interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling 1-800-267-2726.

CSAN® Pronto® is a point-of-care device indicated for use in adult populations only. It is a whole blood analyzer, which involves the collection of a blood specimen. Blood specimens must be collected using the CSAN® Pronto® Test Strips only, which require one drop of blood (about 3.5 µL) to fill. CSAN® Pronto® Test Strips are single use only. All patient samples should be treated as potentially infectious and handled appropriately. Standard precautions should be employed. Personal Protective Equipment should be worn when processing samples, testing quality control, and during maintenance procedures. During use, CSAN® Pronto® should be placed on a stable surface, free from movements and any potential vibrations. Operators are not to move the device from one location to another while in operation.

For more information on the CSAN® Pronto® device, consult the User Manual at [www.CSANPronto.ca](http://www.CSANPronto.ca) prior to operating the device. The manual is also available by calling 1-800-267-2726.

**Reference:**

1. CLOZARIL® Product Monograph. HLS Therapeutics Inc. May 31, 2021.

CLOZARIL, CSAN and CSAN Patient Care Portal + Design are all registered trademarks of Novartis AG. Pronto is a registered trademark of HLS Therapeutics Inc. All rights reserved.

© Copyright 2021 HLS Therapeutics Inc.  
August 2021

HLS Therapeutics Inc.  
10 Carlson Court, Suite 701  
Etobicoke, Ontario  
M9W 6L2

